Home › Therapeutic areas › Renal › Lupus Nephritis

Lupus Nephritis (11 companies)

Companies with an active program in Lupus Nephritis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved $111M 10
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $662M 6
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
CABA Cabaletta Bio DermatologyImmunology+2 Rare 1 Phase 2 $220M 8
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 2 Phase 1 $249M 9
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $602M 10
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $124M 10
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
NKTX Nkarta ImmunologyNeurology+1 Rare 1 Phase 1 $89.6M 8
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $660M 9